Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis.

IF 3.3 3区医学 Q2 RESPIRATORY SYSTEM Therapeutic Advances in Respiratory Disease Pub Date : 2024-01-01 DOI:10.1177/17534666231221771

Junyi Liao, Jia Tang, Yuanping Jiang, Youwen Wang, Jiali Ding, Yong He

{"title":"Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis.","authors":"Junyi Liao, Jia Tang, Yuanping Jiang, Youwen Wang, Jiali Ding, Yong He","doi":"10.1177/17534666231221771","DOIUrl":null,"url":null,"abstract":"Background: With the rise of targeted treatments for asthma, treatment with omalizumab is a new option.Objectives: To assess the improvement of pulmonary function with additional omalizumab treatment in patients (⩾6 years old) with moderate-to-severe allergic asthma.Data sources and methods: Observational studies of randomized controlled trials of add-on omalizumab for the treatment of patients with moderate-to-severe allergic asthma, published from the establishment till August 2022, were retrieved from WAN FANG DATA, PubMed, CNKI, Embase, Cochrane, and Web of Science databases. Data extraction and quality evaluation were performed on the literature that met the inclusion criteria, using RevMan 5.3 to analyze the data.Results: A total of 11 randomized controlled clinical trials were included, involving a total of 3578 patients with asthma, 1856 patients in the omalizumab group, and 1722 patients in the control group. The improvement in Forced expiratory volume in 1 s as a percentage of predicted normal and Forced expiratory volume in 1 s was more pronounced in the omalizumab-treated group [MD = 3.91, 95% confidence interval (CI): 1.89-5.94, p = 0.0002; MD = 0.09, 95% CI: 0.05-0.13, p < 0.0001], while the improvement in Morning Peak expiratory flow rate was not statistically different between the two groups (MD = 3.64, 95% CI: -22.17-29.45, p = 0.78).Conclusion: Additional omalizumab treatment showed some improvement in lung function in patients with moderate-to-severe asthma.Trial registration: PROSPERO ID:CRD42022378498.","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666231221771"},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798107/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Respiratory Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17534666231221771","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: With the rise of targeted treatments for asthma, treatment with omalizumab is a new option.

Objectives: To assess the improvement of pulmonary function with additional omalizumab treatment in patients (⩾6 years old) with moderate-to-severe allergic asthma.

Data sources and methods: Observational studies of randomized controlled trials of add-on omalizumab for the treatment of patients with moderate-to-severe allergic asthma, published from the establishment till August 2022, were retrieved from WAN FANG DATA, PubMed, CNKI, Embase, Cochrane, and Web of Science databases. Data extraction and quality evaluation were performed on the literature that met the inclusion criteria, using RevMan 5.3 to analyze the data.

Results: A total of 11 randomized controlled clinical trials were included, involving a total of 3578 patients with asthma, 1856 patients in the omalizumab group, and 1722 patients in the control group. The improvement in Forced expiratory volume in 1 s as a percentage of predicted normal and Forced expiratory volume in 1 s was more pronounced in the omalizumab-treated group [MD = 3.91, 95% confidence interval (CI): 1.89-5.94, p = 0.0002; MD = 0.09, 95% CI: 0.05-0.13, p < 0.0001], while the improvement in Morning Peak expiratory flow rate was not statistically different between the two groups (MD = 3.64, 95% CI: -22.17-29.45, p = 0.78).

Conclusion: Additional omalizumab treatment showed some improvement in lung function in patients with moderate-to-severe asthma.

Trial registration: PROSPERO ID:CRD42022378498.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

奥马珠单抗对中重度过敏性哮喘患者肺功能的影响：系统综述和荟萃分析。

背景随着哮喘靶向治疗的兴起，使用奥马珠单抗治疗是一种新的选择：评估中重度过敏性哮喘患者（⩾6岁）接受奥马珠单抗附加治疗后肺功能的改善情况：从万方数据（WAN FANG DATA）、PubMed、CNKI、Embase、Cochrane和Web of Science等数据库中检索了自建立至2022年8月期间发表的关于加用奥马珠单抗治疗中重度过敏性哮喘患者的随机对照试验的观察性研究。对符合纳入标准的文献进行了数据提取和质量评估，并使用RevMan 5.3对数据进行分析：结果：共纳入了 11 项随机对照临床试验，涉及 3578 名哮喘患者，其中奥马珠单抗组有 1856 名患者，对照组有 1722 名患者。奥马珠单抗治疗组患者1 s内用力呼气量占预测正常值的百分比和1 s内用力呼气量的改善更为明显[MD = 3.91，95% 置信区间（CI）：1.89-5.94，P = 0.0002；MD = 0.09，95% CI：0.05-0.13，P = 0.78]：结论：追加奥马珠单抗治疗可在一定程度上改善中重度哮喘患者的肺功能：试验注册：PREMCO ID：CRD42022378498。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic Advances in Respiratory Disease RESPIRATORY SYSTEM-

CiteScore

6.90

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.